User: Guest  Login
Less Searchfields
Simple search
Title:

Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Orben, Felix; Lankes, Katharina; Schneeweis, Christian; Hassan, Zonera; Jakubowsky, Hannah; Krauß, Lukas; Boniolo, Fabio; Schneider, Carolin; Schäfer, Arlett; Murr, Janine; Schlag, Christoph; Kong, Bo; Öllinger, Rupert; Wang, Chengdong; Beyer, Georg; Mahajan, Ujjwal M; Xue, Yonggan; Mayerle, Julia; Schmid, Roland M; Kuster, Bernhard; Rad, Roland; Braun, Christian J; Wirth, Matthias; Reichert, Maximilian; Saur, Dieter; Schneider, Günter
Abstract:
Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic dependencies, we conducted a drug screen in pancreatic cancer cell lines. Here, we found that protein arginine N-methyltransferase 5 (PRMT5) inhibitors triggered an MYC-associated dependency. In human and mu...     »
Journal title abbreviation:
JCI Insight
Year:
2022
Journal volume:
7
Journal issue:
10
Fulltext / DOI:
doi:10.1172/jci.insight.151353
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35439169
Print-ISSN:
2379-3708
TUM Institution:
611; Klinik und Poliklinik für Innere Medizin II, Gastroenterologie; Lehrstuhl für Translationale Tumorforschung (DKTK) (Prof. Saur); Professur für Molekulare Onkologie und Funktionelle Genomik (Prof. Rad)
 BibTeX